Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.

欧洲行为药理学会 (EBPS) 官方期刊

《精神药理学》是一本国际期刊，涵盖阐明药物影响行为的机制这一广泛主题。该期刊的范围涵盖以下领域：

人类精神药理学：实验

本部分包括描述药物对人类情绪、行为、认知和生理影响的稿件。该期刊鼓励提交涉及脑成像、遗传学、神经内分泌学和发育主题的稿件。本部分中的稿件通常描述在受控条件下进行的研究，但偶尔也会考虑描述性或观察性研究。

人类精神药理学：临床和转化

本部分包括涉及药物和精神疾病广泛交集的研究。这不仅包括临床试验和药物使用和代谢、药物监测和药物流行病学的研究，还包括利用各种临床相关方法的工作，包括神经影像学、药物遗传学、认知科学、生物标志物等。特别鼓励将临床前知识转化为临床知识的工作。提交到本节的主要特点是它们涉及临床方面。

临床前精神药理学：行为和神经

本节考虑具有明确化学结构的化合物对人类以外物种的行为任何方面的影响的报告，特别是与神经化学效应相关时。欢迎包含与行为相结合的神经科学技术的稿件。我们鼓励报告在行为和分子水平上深入了解药物作用机制的研究。

临床前精神药理学：转化

本部分考虑使用与疾病相关的临床前模型和测试来增强对可能对精神病或神经病患者具有治疗价值的核心机制的信心的手稿，或报告可能转化为临床的临床前操作和挑战的手稿。旨在根据临床发现（反向翻译）改进临床前模型的研究也将受到考虑。该期刊特别鼓励提交整合靶组织暴露测量、分子靶标活性和/或靶向生化途径调节的投稿。

临床前精神药理学：分子、遗传和表观遗传

本部分重点介绍神经药理学药剂/药物的分子和细胞作用，以及影响健康和疾病中枢神经系统的药物靶标的识别/验证。我们特别鼓励在分子水平上深入了解药物作用机制的研究。欢迎包含遗传或表观遗传对神经化学或行为影响的证据的稿件。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-精神病学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为3.5，平均审稿速度为 较快,2-4周 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。